Phibro Animal Health Corp
NASDAQ:PAHC
Phibro Animal Health Corp
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. The company is headquartered in Teaneck, New Jersey and currently employs 1,725 full-time employees. The company went IPO on 2014-04-11. The firm operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The firm develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The firm sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The firm's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Strong Sales Growth: Phibro delivered 21% higher consolidated sales in Q2, driven by a 26% jump in Animal Health, especially Medicated Feed Additives.
Profitability Surge: Adjusted EBITDA rose 41% and adjusted net income climbed 60% year-over-year, reflecting strong demand and favorable mix.
Upbeat Guidance: Full-year sales, EBITDA, and adjusted net income guidance were raised, citing strong momentum and integration of the MFA portfolio.
Operational Momentum: Management highlighted robust customer demand, improved execution, and positive feedback from industry events.
Leadership Transition: CEO succession will occur in July, with the current CEO remaining as Executive Chairman to ensure continuity.
Margin Drivers: Higher prices, favorable product mix, and focus on high-margin products boosted gross margin.
Positive Market Environment: Protein markets remain strong and stable, supporting demand across livestock segments.
